Guest guest Posted January 8, 2008 Report Share Posted January 8, 2008 YEAH, Beauties for our beauty. YEAH Love and Prayers, Peggy ipf 6/04 Florida"Worry looks around, Sorry looks back, Faith looks up." I am so excited!!!! I finally got my M-6 tanks today and they are so cute AND!!!! they left me both conservators and extra plastic keys. I feel like I won the jackpot. No more ugly Ednas for me. I may need to go buy new makeup to celebrate my new look. Tiny tanks Sarcoid/PF 3/2006 California Harvard Medical School Health BeatOne of the top medical news stories of 2007: When it’s under control, inflammation is a normal part of our immune response. But when it gets out of control, inflammation causes disease and pain, and fanning the flames is a protein called tumor necrosis factor-alpha (TNF-alpha).In the 1990s, researchers genetically engineered a protein that blocks TNF-alpha. The FDA approved the fruits of this labor, etanercept (Enbrel), in 1998.Now two others — infliximab (Remicade) and adalimumab (Humira) — are on the market, and a third — certolizumab — is waiting in the wings.The medications have greatly improved the treatment of several inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (a condition that affects the spine and the sacroiliac joints), and Crohn’s disease, a bowel disorder. A combination of a TNF-alpha blocker and methotrexate, a standard antirheumatic drug, is twice as effective as methotrexate alone in the treatment of rheumatoid arthritis. Sales of the TNF-alpha blockers have more than tripled since 2002, according to IMS Health.The TNF-alpha blockers have serious drawbacks: they’re expensive ($10,000 to $25,000 annually per patient), can result in serious infections, and have been linked to cancer, particularly lymphoma. But by tackling inflammation at its roots, they may be paving the way for a new approach to treating many diseases. In 2007, National Institutes of Health researchers proposed using TNF-alpha inhibition to treat brain diseases with an inflammatory component, such as Alzheimer’s and Parkinson’s disease. Thought it was interesting. .. Leanne uip 1/03 Illinoislisted for single lung transplant 10-12-07Never miss a thing. Make Yahoo your homepage.Never miss a thing. Make Yahoo your homepage. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 9, 2008 Report Share Posted January 9, 2008 ... I'm happy for you that your ugly Edna is gone. Yeah, you need new makeup for TT. for sure! lol Mama-Sher, 69; IPF, 3-06, OR.Don't fret about tomorrow, God is already there! Harvard Medical School Health Beat One of the top medical news stories of 2007: When it’s under control, inflammation is a normal part of our immune response. But when it gets out of control, inflammation causes disease and pain, and fanning the flames is a protein called tumor necrosis factor-alpha (TNF-alpha). In the 1990s, researchers genetically engineered a protein that blocks TNF-alpha. The FDA approved the fruits of this labor, etanercept (Enbrel), in 1998. Now two others — infliximab (Remicade) and adalimumab (Humira) — are on the market, and a third — certolizumab — is waiting in the wings. The medications have greatly improved the treatment of several inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (a condition that affects the spine and the sacroiliac joints), and Crohn’s disease, a bowel disorder. A combination of a TNF-alpha blocker and methotrexate, a standard antirheumatic drug, is twice as effective as methotrexate alone in the treatment of rheumatoid arthritis. Sales of the TNF-alpha blockers have more than tripled since 2002, according to IMS Health. The TNF-alpha blockers have serious drawbacks: they’re expensive ($10,000 to $25,000 annually per patient), can result in serious infections, and have been linked to cancer, particularly lymphoma. But by tackling inflammation at its roots, they may be paving the way for a new approach to treating many diseases. In 2007, National Institutes of Health researchers proposed using TNF-alpha inhibition to treat brain diseases with an inflammatory component, such as Alzheimer’s and Parkinson’s disease. Thought it was interesting. .. Leanne uip 1/03 Illinois listed for single lung transplant 10-12-07 Never miss a thing. Make Yahoo your homepage. Never miss a thing. Make Yahoo your homepage. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 9, 2008 Report Share Posted January 9, 2008 Joyce, I am interested. Right now I have two regulators one for pulse, one for continuous, but it would be nice not to have to switch. By the way I loved your analogy on heaven. Thanks for sharing it. Sarcoid/PF 3/2006 California Harvard Medical School Health Beat> > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > One of the top medical news stories of 2007:> > > > When it's under control, inflammation is a normal part of our immune response. But when it gets out of control, inflammation causes disease and pain, and fanning the flames is a protein called tumor necrosis factor-alpha (TNF-alpha).> > In the 1990s, researchers genetically engineered a protein that blocks TNF-alpha. The FDA approved the fruits of this labor, etanercept (Enbrel), in 1998.> > Now two others — infliximab (Remicade) and adalimumab (Humira) — are on the market, and a third — certolizumab — is waiting in the wings.> > The medications have greatly improved the treatment of several inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (a condition that affects the spine and the sacroiliac joints), and Crohn's disease, a bowel disorder. A combination of a TNF-alpha blocker and methotrexate, a standard> > antirheumatic drug, is twice as effective as methotrexate alone in the treatment of rheumatoid arthritis. Sales of the TNF-alpha blockers have more than tripled since 2002, according to IMS Health.> > The TNF-alpha blockers have serious drawbacks: they're expensive ($10,000 to $25,000 annually per patient), can result in serious infections, and have been linked to cancer, particularly lymphoma. But by tackling inflammation at its roots, they may be paving the way for a new approach to treating many diseases. In 2007, National Institutes of Health researchers proposed using TNF-alpha inhibition to treat brain diseases with an inflammatory component, such as Alzheimer's and Parkinson's disease.> > > > > > > > Thought it was interesting. ..> > > > Leanne uip 1/03 Illinois> > listed for single lung transplant 10-12-07> > > > > > > > Never miss a thing. Make Yahoo your homepage.> > > > > > > > > > > > > > > > > > > > > > > > > > <!--> > > > #ygrp-mkp{> > border:1px solid #d8d8d8;font- family:Arial; margin:14px 0px;padding: 0px 14px;}> > #ygrp-mkp hr{> > border:1px solid #d8d8d8;}> > #ygrp-mkp #hd{> > color:#628c2a; font-size: 85%;font- weight:bold; line-height: 122%;margin: 10px 0px;}> > #ygrp-mkp #ads{> > margin-bottom: 10px;}> > #ygrp-mkp .ad{> > padding:0 0;}> > #ygrp-mkp .ad a{> > color:#0000ff; text-decoration: none;}> > -->> > > > > > > > <!--> > > > #ygrp-sponsor #ygrp-lc{> > font-family: Arial;}> > #ygrp-sponsor #ygrp-lc #hd{> > margin:10px 0px;font-weight: bold;font- size:78%; line-height: 122%;}> > #ygrp-sponsor #ygrp-lc .ad{> > margin-bottom: 10px;padding: 0 0;}> > -->> > > > > > > > <!--> > > > #ygrp-mlmsg {font-size:13px; font-family: arial, helvetica, clean, sans-serif;}> > #ygrp-mlmsg table {font-size:inherit; font:100% ;}> > #ygrp-mlmsg select, input, textarea {font:99% arial, helvetica, clean, sans-serif;}> > #ygrp-mlmsg pre, code {font:115% monospace;}> > #ygrp-mlmsg * {line-height: 1.22em;}> > #ygrp-text{> > font-family: Georgia;> > }> > #ygrp-text p{> > margin:0 0 1em 0;}> > #ygrp-tpmsgs{> > font-family: Arial;> > clear:both;}> > #ygrp-vitnav{> > padding-top: 10px;font- family:Verdana; font-size: 77%;margin: 0;}> > #ygrp-vitnav a{> > padding:0 1px;}> > #ygrp-actbar{> > clear:both;margin: 25px 0;white-space: nowrap;color: #666;text- align:right; }> > #ygrp-actbar .left{> > float:left;white- space:nowrap; }> > .bld{font-weight: bold;}> > #ygrp-grft{> > font-family: Verdana;font- size:77%; padding:15px 0;}> > #ygrp-ft{> > font-family: verdana;font- size:77%; border-top: 1px solid #666;> > padding:5px 0;> > }> > #ygrp-mlmsg #logo{> > padding-bottom: 10px;}> > > > #ygrp-vital{> > background-color: #e0ecee;margin- bottom:20px; padding:2px 0 8px 8px;}> > #ygrp-vital #vithd{> > font-size:77% ;font-family: Verdana;font- weight:bold; color:#333; text-transform: uppercase; }> > #ygrp-vital ul{> > padding:0;margin: 2px 0;}> > #ygrp-vital ul li{> > list-style-type: none;clear: both;border: 1px solid #e0ecee;> > }> > #ygrp-vital ul li .ct{> > font-weight: bold;color: #ff7900;float: right;width: 2em;text- align:right; padding-right: .5em;}> > #ygrp-vital ul li .cat{> > font-weight: bold;}> > #ygrp-vital a{> > text-decoration: none;}> > > > #ygrp-vital a:hover{> > text-decoration: underline; }> > > > #ygrp-sponsor #hd{> > color:#999;font- size:77%; }> > #ygrp-sponsor #ov{> > padding:6px 13px;background- color:#e0ecee; margin-bottom: 20px;}> > #ygrp-sponsor #ov ul{> > padding:0 0 0 8px;margin:0; }> > #ygrp-sponsor #ov li{> > list-style-type: square;padding: 6px 0;font-size: 77%;}> > #ygrp-sponsor #ov li a{> > text-decoration: none;font- size:130% ;}> > #ygrp-sponsor #nc{> > background-color: #eee;margin- bottom:20px; padding:0 8px;}> > #ygrp-sponsor .ad{> > padding:8px 0;}> > #ygrp-sponsor .ad #hd1{> > font-family: Arial;font- weight:bold; color:#628c2a; font-size: 100%;line- height:122% ;}> > #ygrp-sponsor .ad a{> > text-decoration: none;}> > #ygrp-sponsor .ad a:hover{> > text-decoration: underline; }> > #ygrp-sponsor .ad p{> > margin:0;}> > o{font-size: 0;}> > .MsoNormal{> > margin:0 0 0 0;}> > #ygrp-text tt{> > font-size:120% ;}> > blockquote{margin: 0 0 0 4px;}> > .replbq{margin: 4;}> > -->> > > > > > > > > > > > > > > > > > ____________ _________ _________ _________ _________ _________ _________ _________ _________> > Be a better friend, newshound, and > > know-it-all with Yahoo! Mobile. Try it now. http://mobile. yahoo.com/ ;_ylt=Ahu06i62sR 8HDtDypao8Wcj9tA cJ> >> > > > > > > > > > > > > <!--> > #ygrp-mkp{> border:1px solid #d8d8d8;font- family:Arial; margin:14px 0px;padding: 0px 14px;}> #ygrp-mkp hr{> border:1px solid #d8d8d8;}> #ygrp-mkp #hd{> color:#628c2a; font-size: 85%;font- weight:bold; line-height: 122%;margin: 10px 0px;}> #ygrp-mkp #ads{> margin-bottom: 10px;}> #ygrp-mkp .ad{> padding:0 0;}> #ygrp-mkp .ad a{> color:#0000ff; text-decoration: none;}> -->> > > > <!--> > #ygrp-sponsor #ygrp-lc{> font-family: Arial;}> #ygrp-sponsor #ygrp-lc #hd{> margin:10px 0px;font-weight: bold;font- size:78%; line-height: 122%;}> #ygrp-sponsor #ygrp-lc .ad{> margin-bottom: 10px;padding: 0 0;}> -->> > > > <!--> > #ygrp-mlmsg {font-size:13px; font-family: arial, helvetica, clean, sans-serif;}> #ygrp-mlmsg table {font-size:inherit; font:100% ;}> #ygrp-mlmsg select, input, textarea {font:99% arial, helvetica, clean, sans-serif;}> #ygrp-mlmsg pre, code {font:115% monospace;}> #ygrp-mlmsg * {line-height: 1.22em;}> #ygrp-text{> font-family: Georgia;> }> #ygrp-text p{> margin:0 0 1em 0;}> #ygrp-tpmsgs{> font-family: Arial;> clear:both;}> #ygrp-vitnav{> padding-top: 10px;font- family:Verdana; font-size: 77%;margin: 0;}> #ygrp-vitnav a{> padding:0 1px;}> #ygrp-actbar{> clear:both;margin: 25px 0;white-space: nowrap;color: #666;text- align:right; }> #ygrp-actbar .left{> float:left;white- space:nowrap; }> .bld{font-weight: bold;}> #ygrp-grft{> font-family: Verdana;font- size:77%; padding:15px 0;}> #ygrp-ft{> font-family: verdana;font- size:77%; border-top: 1px solid #666;> padding:5px 0;> }> #ygrp-mlmsg #logo{> padding-bottom: 10px;}> > #ygrp-vital{> background-color: #e0ecee;margin- bottom:20px; padding:2px 0 8px 8px;}> #ygrp-vital #vithd{> font-size:77% ;font-family: Verdana;font- weight:bold; color:#333; text-transform: uppercase; }> #ygrp-vital ul{> padding:0;margin: 2px 0;}> #ygrp-vital ul li{> list-style-type: none;clear: both;border: 1px solid #e0ecee;> }> #ygrp-vital ul li .ct{> font-weight: bold;color: #ff7900;float: right;width: 2em;text- align:right; padding-right: .5em;}> #ygrp-vital ul li .cat{> font-weight: bold;}> #ygrp-vital a{> text-decoration: none;}> > #ygrp-vital a:hover{> text-decoration: underline; }> > #ygrp-sponsor #hd{> color:#999;font- size:77%; }> #ygrp-sponsor #ov{> padding:6px 13px;background- color:#e0ecee; margin-bottom: 20px;}> #ygrp-sponsor #ov ul{> padding:0 0 0 8px;margin:0; }> #ygrp-sponsor #ov li{> list-style-type: square;padding: 6px 0;font-size: 77%;}> #ygrp-sponsor #ov li a{> text-decoration: none;font- size:130% ;}> #ygrp-sponsor #nc{> background-color: #eee;margin- bottom:20px; padding:0 8px;}> #ygrp-sponsor .ad{> padding:8px 0;}> #ygrp-sponsor .ad #hd1{> font-family: Arial;font- weight:bold; color:#628c2a; font-size: 100%;line- height:122% ;}> #ygrp-sponsor .ad a{> text-decoration: none;}> #ygrp-sponsor .ad a:hover{> text-decoration: underline; }> #ygrp-sponsor .ad p{> margin:0;}> o{font-size: 0;}> .MsoNormal{> margin:0 0 0 0;}> #ygrp-text tt{> font-size:120% ;}> blockquote{margin: 0 0 0 4px;}> .replbq{margin: 4;}> -->> > > > > > > > > > ____________ _________ _________ _________ _________ _________ _________ _________ _________> Looking for last minute shopping deals? > Find them fast with Yahoo! Search. http://tools. search.yahoo. com/newsearch/ category. php?category= shopping> Looking for last minute shopping deals? Find them fast with Yahoo! Search. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 9, 2008 Report Share Posted January 9, 2008 Thank you Joyce. Sarcoid/PF 3/2006 California Harvard Medical School Health Beat> > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > One of the top medical news stories of 2007:> > > > > > When it's under control, inflammation is a normal part of our immune response. But when it gets out of control, inflammation causes disease and pain, and fanning the flames is a protein called tumor necrosis factor-alpha (TNF-alpha).> > > In the 1990s, researchers genetically engineered a protein that blocks TNF-alpha. The FDA approved the fruits of this labor, etanercept (Enbrel), in 1998.> > > Now two others — infliximab (Remicade) and adalimumab (Humira) — are on the market, and a third — certolizumab — is waiting in the wings.> > > The medications have greatly improved the treatment of several inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (a condition that affects the spine and the sacroiliac joints), and Crohn's disease, a bowel disorder. A combination of a TNF-alpha blocker and methotrexate, a standard> > > antirheumatic drug, is twice as effective as methotrexate alone in the treatment of rheumatoid arthritis. Sales of the TNF-alpha blockers have more than tripled since 2002, according to IMS Health.> > > The TNF-alpha blockers have serious drawbacks: they're expensive ($10,000 to $25,000 annually per patient), can result in serious infections, and have been linked to cancer, particularly lymphoma. But by tackling inflammation at its roots, they may be paving the way for a new approach to treating many diseases. In 2007, National Institutes of Health researchers proposed using TNF-alpha inhibition to treat brain diseases with an inflammatory component, such as Alzheimer's and Parkinson's disease.> > > > > > > > > > > > Thought it was interesting. ..> > > > > > Leanne uip 1/03 Illinois> > > listed for single lung transplant 10-12-07> > > > > > > > > > > > Never miss a thing. Make Yahoo your homepage.> > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > <!--> > > > > > #ygrp-mkp{> > > border:1px solid #d8d8d8;font- family:Arial; margin:14px 0px;padding: 0px 14px;}> > > #ygrp-mkp hr{> > > border:1px solid #d8d8d8;}> > > #ygrp-mkp #hd{> > > color:#628c2a; font-size: 85%;font- weight:bold; line-height: 122%;margin: 10px 0px;}> > > #ygrp-mkp #ads{> > > margin-bottom: 10px;}> > > #ygrp-mkp .ad{> > > padding:0 0;}> > > #ygrp-mkp .ad a{> > > color:#0000ff; text-decoration: none;}> > > -->> > > > > > > > > > > > <!--> > > > > > #ygrp-sponsor #ygrp-lc{> > > font-family: Arial;}> > > #ygrp-sponsor #ygrp-lc #hd{> > > margin:10px 0px;font-weight: bold;font- size:78%; line-height: 122%;}> > > #ygrp-sponsor #ygrp-lc .ad{> > > margin-bottom: 10px;padding: 0 0;}> > > -->> > > > > > > > > > > > <!--> > > > > > #ygrp-mlmsg {font-size:13px; font-family: arial, helvetica, clean, sans-serif;}> > > #ygrp-mlmsg table {font-size:inherit; font:100% ;}> > > #ygrp-mlmsg select, input, textarea {font:99% arial, helvetica, clean, sans-serif;}> > > #ygrp-mlmsg pre, code {font:115% monospace;}> > > #ygrp-mlmsg * {line-height: 1.22em;}> > > #ygrp-text{> > > font-family: Georgia;> > > }> > > #ygrp-text p{> > > margin:0 0 1em 0;}> > > #ygrp-tpmsgs{> > > font-family: Arial;> > > clear:both;}> > > #ygrp-vitnav{> > > padding-top: 10px;font- family:Verdana; font-size: 77%;margin: 0;}> > > #ygrp-vitnav a{> > > padding:0 1px;}> > > #ygrp-actbar{> > > clear:both;margin: 25px 0;white-space: nowrap;color: #666;text- align:right; }> > > #ygrp-actbar .left{> > > float:left;white- space:nowrap; }> > > .bld{font-weight: bold;}> > > #ygrp-grft{> > > font-family: Verdana;font- size:77%; padding:15px 0;}> > > #ygrp-ft{> > > font-family: verdana;font- size:77%; border-top: 1px solid #666;> > > padding:5px 0;> > > }> > > #ygrp-mlmsg #logo{> > > padding-bottom: 10px;}> > > > > > #ygrp-vital{> > > background-color: #e0ecee;margin- bottom:20px; padding:2px 0 8px 8px;}> > > #ygrp-vital #vithd{> > > font-size:77% ;font-family: Verdana;font- weight:bold; color:#333; text-transform: uppercase; }> > > #ygrp-vital ul{> > > padding:0;margin: 2px 0;}> > > #ygrp-vital ul li{> > > list-style-type: none;clear: both;border: 1px solid #e0ecee;> > > }> > > #ygrp-vital ul li .ct{> > > font-weight: bold;color: #ff7900;float: right;width: 2em;text- align:right; padding-right: .5em;}> > > #ygrp-vital ul li .cat{> > > font-weight: bold;}> > > #ygrp-vital a{> > > text-decoration: none;}> > > > > > #ygrp-vital a:hover{> > > text-decoration: underline; }> > > > > > #ygrp-sponsor #hd{> > > color:#999;font- size:77%; }> > > #ygrp-sponsor #ov{> > > padding:6px 13px;background- color:#e0ecee; margin-bottom: 20px;}> > > #ygrp-sponsor #ov ul{> > > padding:0 0 0 8px;margin:0; }> > > #ygrp-sponsor #ov li{> > > list-style-type: square;padding: 6px 0;font-size: 77%;}> > > #ygrp-sponsor #ov li a{> > > text-decoration: none;font- size:130% ;}> > > #ygrp-sponsor #nc{> > > background-color: #eee;margin- bottom:20px; padding:0 8px;}> > > #ygrp-sponsor .ad{> > > padding:8px 0;}> > > #ygrp-sponsor .ad #hd1{> > > font-family: Arial;font- weight:bold; color:#628c2a; font-size: 100%;line- height:122% ;}> > > #ygrp-sponsor .ad a{> > > text-decoration: none;}> > > #ygrp-sponsor .ad a:hover{> > > text-decoration: underline; }> > > #ygrp-sponsor .ad p{> > > margin:0;}> > > o{font-size: 0;}> > > ..MsoNormal{> > > margin:0 0 0 0;}> > > #ygrp-text tt{> > > font-size:120% ;}> > > blockquote{margin: 0 0 0 4px;}> > > .replbq{margin: 4;}> > > -->> > > > > > > > > > > > > > > > > > > > > > > > > > > ____________ _________ _________ _________ _________ _________ _________ _________ _________> > > Be a better friend, newshound, and > > > know-it-all with Yahoo! Mobile. Try it now. http://mobile. yahoo.com/ ;_ylt=Ahu06i62sR 8HDtDypao8Wcj9tA cJ> > >> > > > > > > > > > > > > > > > > > > > > > > > > > <!--> > > > #ygrp-mkp{> > border:1px solid #d8d8d8;font- family:Arial; margin:14px 0px;padding: 0px 14px;}> > #ygrp-mkp hr{> > border:1px solid #d8d8d8;}> > #ygrp-mkp #hd{> > color:#628c2a; font-size: 85%;font- weight:bold; line-height: 122%;margin: 10px 0px;}> > #ygrp-mkp #ads{> > margin-bottom: 10px;}> > #ygrp-mkp .ad{> > padding:0 0;}> > #ygrp-mkp .ad a{> > color:#0000ff; text-decoration: none;}> > -->> > > > > > > > <!--> > > > #ygrp-sponsor #ygrp-lc{> > font-family: Arial;}> > #ygrp-sponsor #ygrp-lc #hd{> > margin:10px 0px;font-weight: bold;font- size:78%; line-height: 122%;}> > #ygrp-sponsor #ygrp-lc .ad{> > margin-bottom: 10px;padding: 0 0;}> > -->> > > > > > > > <!--> > > > #ygrp-mlmsg {font-size:13px; font-family: arial, helvetica, clean, sans-serif;}> > #ygrp-mlmsg table {font-size:inherit; font:100% ;}> > #ygrp-mlmsg select, input, textarea {font:99% arial, helvetica, clean, sans-serif;}> > #ygrp-mlmsg pre, code {font:115% monospace;}> > #ygrp-mlmsg * {line-height: 1.22em;}> > #ygrp-text{> > font-family: Georgia;> > }> > #ygrp-text p{> > margin:0 0 1em 0;}> > #ygrp-tpmsgs{> > font-family: Arial;> > clear:both;}> > #ygrp-vitnav{> > padding-top: 10px;font- family:Verdana; font-size: 77%;margin: 0;}> > #ygrp-vitnav a{> > padding:0 1px;}> > #ygrp-actbar{> > clear:both;margin: 25px 0;white-space: nowrap;color: #666;text- align:right; }> > #ygrp-actbar ..left{> > float:left;white- space:nowrap; }> > .bld{font-weight: bold;}> > #ygrp-grft{> > font-family: Verdana;font- size:77%; padding:15px 0;}> > #ygrp-ft{> > font-family: verdana;font- size:77%; border-top: 1px solid #666;> > padding:5px 0;> > }> > #ygrp-mlmsg #logo{> > padding-bottom: 10px;}> > > > #ygrp-vital{> > background-color: #e0ecee;margin- bottom:20px; padding:2px 0 8px 8px;}> > #ygrp-vital #vithd{> > font-size:77% ;font-family: Verdana;font- weight:bold; color:#333; text-transform: uppercase; }> > #ygrp-vital ul{> > padding:0;margin: 2px 0;}> > #ygrp-vital ul li{> > list-style-type: none;clear: both;border: 1px solid #e0ecee;> > }> > #ygrp-vital ul li .ct{> > font-weight: bold;color: #ff7900;float: right;width: 2em;text- align:right; padding-right: .5em;}> > #ygrp-vital ul li .cat{> > font-weight: bold;}> > #ygrp-vital a{> > text-decoration: none;}> > > > #ygrp-vital a:hover{> > text-decoration: underline; }> > > > #ygrp-sponsor #hd{> > color:#999;font- size:77%; }> > #ygrp-sponsor #ov{> > padding:6px 13px;background- color:#e0ecee; margin-bottom: 20px;}> > #ygrp-sponsor #ov ul{> > padding:0 0 0 8px;margin:0; }> > #ygrp-sponsor #ov li{> > list-style-type: square;padding: 6px 0;font-size: 77%;}> > #ygrp-sponsor #ov li a{> > text-decoration: none;font- size:130% ;}> > #ygrp-sponsor #nc{> > background-color: #eee;margin- bottom:20px; padding:0 8px;}> > #ygrp-sponsor .ad{> > padding:8px 0;}> > #ygrp-sponsor .ad #hd1{> > font-family: Arial;font- weight:bold; color:#628c2a; font-size: 100%;line- height:122% ;}> > #ygrp-sponsor .ad a{> > text-decoration: none;}> > #ygrp-sponsor .ad a:hover{> > text-decoration: underline; }> > #ygrp-sponsor .ad p{> > margin:0;}> > o{font-size: 0;}> > .MsoNormal{> > margin:0 0 0 0;}> > #ygrp-text tt{> > font-size:120% ;}> > blockquote{margin: 0 0 0 4px;}> > .replbq{margin: 4;}> > -->> > > > > > > > > > > > > > > > > > > > ____________ _________ _________ _________ _________ _________ _________ _________ _________> > Looking for last minute shopping deals? > > Find them fast with Yahoo! Search. http://tools. search.yahoo. com/newsearch/ category. php?category= shopping> >> > > > > > > > > > > > > <!--> > #ygrp-mkp{> border:1px solid #d8d8d8;font- family:Arial; margin:14px 0px;padding: 0px 14px;}> #ygrp-mkp hr{> border:1px solid #d8d8d8;}> #ygrp-mkp #hd{> color:#628c2a; font-size: 85%;font- weight:bold; line-height: 122%;margin: 10px 0px;}> #ygrp-mkp #ads{> margin-bottom: 10px;}> #ygrp-mkp .ad{> padding:0 0;}> #ygrp-mkp .ad a{> color:#0000ff; text-decoration: none;}> -->> > > > <!--> > #ygrp-sponsor #ygrp-lc{> font-family: Arial;}> #ygrp-sponsor #ygrp-lc #hd{> margin:10px 0px;font-weight: bold;font- size:78%; line-height: 122%;}> #ygrp-sponsor #ygrp-lc .ad{> margin-bottom: 10px;padding: 0 0;}> -->> > > > <!--> > #ygrp-mlmsg {font-size:13px; font-family: arial, helvetica, clean, sans-serif;}> #ygrp-mlmsg table {font-size:inherit; font:100% ;}> #ygrp-mlmsg select, input, textarea {font:99% arial, helvetica, clean, sans-serif;}> #ygrp-mlmsg pre, code {font:115% monospace;}> #ygrp-mlmsg * {line-height: 1.22em;}> #ygrp-text{> font-family: Georgia;> }> #ygrp-text p{> margin:0 0 1em 0;}> #ygrp-tpmsgs{> font-family: Arial;> clear:both;}> #ygrp-vitnav{> padding-top: 10px;font- family:Verdana; font-size: 77%;margin: 0;}> #ygrp-vitnav a{> padding:0 1px;}> #ygrp-actbar{> clear:both;margin: 25px 0;white-space: nowrap;color: #666;text- align:right; }> #ygrp-actbar .left{> float:left;white- space:nowrap; }> .bld{font-weight: bold;}> #ygrp-grft{> font-family: Verdana;font- size:77%; padding:15px 0;}> #ygrp-ft{> font-family: verdana;font- size:77%; border-top: 1px solid #666;> padding:5px 0;> }> #ygrp-mlmsg #logo{> padding-bottom: 10px;}> > #ygrp-vital{> background-color: #e0ecee;margin- bottom:20px; padding:2px 0 8px 8px;}> #ygrp-vital #vithd{> font-size:77% ;font-family: Verdana;font- weight:bold; color:#333; text-transform: uppercase; }> #ygrp-vital ul{> padding:0;margin: 2px 0;}> #ygrp-vital ul li{> list-style-type: none;clear: both;border: 1px solid #e0ecee;> }> #ygrp-vital ul li .ct{> font-weight: bold;color: #ff7900;float: right;width: 2em;text- align:right; padding-right: .5em;}> #ygrp-vital ul li .cat{> font-weight: bold;}> #ygrp-vital a{> text-decoration: none;}> > #ygrp-vital a:hover{> text-decoration: underline; }> > #ygrp-sponsor #hd{> color:#999;font- size:77%; }> #ygrp-sponsor #ov{> padding:6px 13px;background- color:#e0ecee; margin-bottom: 20px;}> #ygrp-sponsor #ov ul{> padding:0 0 0 8px;margin:0; }> #ygrp-sponsor #ov li{> list-style-type: square;padding: 6px 0;font-size: 77%;}> #ygrp-sponsor #ov li a{> text-decoration: none;font- size:130% ;}> #ygrp-sponsor #nc{> background-color: #eee;margin- bottom:20px; padding:0 8px;}> #ygrp-sponsor .ad{> padding:8px 0;}> #ygrp-sponsor .ad #hd1{> font-family: Arial;font- weight:bold; color:#628c2a; font-size: 100%;line- height:122% ;}> #ygrp-sponsor .ad a{> text-decoration: none;}> #ygrp-sponsor .ad a:hover{> text-decoration: underline; }> #ygrp-sponsor .ad p{> margin:0;}> o{font-size: 0;}> .MsoNormal{> margin:0 0 0 0;}> #ygrp-text tt{> font-size:120% ;}> blockquote{margin: 0 0 0 4px;}> .replbq{margin: 4;}> -->> > > > > > > > > ____________ _________ _________ _________ _________ _________ _________ _________ _________> Never miss a thing. Make Yahoo your home page. > http://www.yahoo. com/r/hs> Never miss a thing. Make Yahoo your homepage. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.